Business Description
ISIN : US1255231003
Total Employee Number:
67,700Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 0.75 | |||||
Debt-to-EBITDA | 2.49 | |||||
Interest Coverage | 6.27 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.78 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.2 | |||||
3-Year EBITDA Growth Rate | 3.5 | |||||
3-Year EPS without NRI Growth Rate | 8.5 | |||||
3-Year FCF Growth Rate | 9.9 | |||||
3-Year Book Growth Rate | 1.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.71 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.91 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.44 | |||||
9-Day RSI | 53.49 | |||||
14-Day RSI | 51.62 | |||||
3-1 Month Momentum % | -2.36 | |||||
6-1 Month Momentum % | -3.75 | |||||
12-1 Month Momentum % | -9.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.85 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.13 | |||||
Days Inventory | 8.71 | |||||
Days Sales Outstanding | 38.67 | |||||
Days Payable | 63.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.17 | |||||
Dividend Payout Ratio | 0.2 | |||||
3-Year Dividend Growth Rate | 10.5 | |||||
Forward Dividend Yield % | 2.21 | |||||
5-Year Yield-on-Cost % | 90.14 | |||||
3-Year Average Share Buyback Ratio | 4.1 | |||||
Shareholder Yield % | 2.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 8.8 | |||||
Operating Margin % | 3.17 | |||||
Net Margin % | 2.28 | |||||
EBITDA Margin % | 4.54 | |||||
FCF Margin % | 3.24 | |||||
OCF Margin % | 3.65 | |||||
ROE % | 15.38 | |||||
ROA % | 4.12 | |||||
ROIC % | 6.42 | |||||
3-Year ROIIC % | -11.5 | |||||
ROC (Joel Greenblatt) % | 273.96 | |||||
ROCE % | 10.06 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.69 | |||||
Forward PE Ratio | 8.43 | |||||
PE Ratio without NRI | 8.97 | |||||
Shiller PE Ratio | 14.97 | |||||
Price-to-Owner-Earnings | 8.67 | |||||
PEG Ratio | 8.15 | |||||
PS Ratio | 0.27 | |||||
PB Ratio | 1.75 | |||||
Price-to-Free-Cash-Flow | 8.26 | |||||
Price-to-Operating-Cash-Flow | 7.32 | |||||
EV-to-EBIT | 9.9 | |||||
EV-to-Forward-EBIT | 12.17 | |||||
EV-to-EBITDA | 7.79 | |||||
EV-to-Forward-EBITDA | 8.28 | |||||
EV-to-Revenue | 0.35 | |||||
EV-to-Forward-Revenue | 0.33 | |||||
EV-to-FCF | 10.94 | |||||
Price-to-GF-Value | 0.73 | |||||
Price-to-Projected-FCF | 0.49 | |||||
Price-to-Median-PS-Value | 0.52 | |||||
Earnings Yield (Greenblatt) % | 10.1 | |||||
FCF Yield % | 12.21 | |||||
Forward Rate of Return (Yacktman) % | 12.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:CI
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
The Cigna Group Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 281,336 | ||
| EPS (TTM) ($) | 24.17 | ||
| Beta | 0.0119 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.07 | ||
| Volatility % | 25.92 | ||
| 14-Day RSI | 51.62 | ||
| 14-Day ATR ($) | 6.280128 | ||
| 20-Day SMA ($) | 279.069 | ||
| 12-1 Month Momentum % | -9.86 | ||
| 52-Week Range ($) | 239.51 - 315.47 | ||
| Shares Outstanding (Mil) | 264.24 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
The Cigna Group Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
The Cigna Group Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 174 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-05 08:30 | In 154 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-05 | In 153 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 56 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 55 days | ||
| USD 1.560000 Cash Dividend | 2026-09-08 | In 3 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:30 | 296.47 (-2.16%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 06:30 | 296.47 (-2.16%) | ||
| USD 1.560000 Cash Dividend | 2026-06-04 | 270.73 (-0.65%) | ||
| Guidance call for 2026 | 2026-05-13 12:20 | 298.49 (+2.93%) |
The Cigna Group Frequently Asked Questions
Guru Commentaries on NYSE:CI
Cigna (+19.7%) delivered strong gains in the quarter following better-than-expected fourth quarter earnings, driven by continued strength in the Evernorth pharmacy benefit segment. Management reaffirmed 2025 guidance and announced leadership changes, including the promotion of Brian Evanko to Chief Operating Officer. With the Medicare divestiture complete, the company is focused on streamlining operations and improving margins. While elevated medical loss ratios persist in stop-loss, repricing is underway and core earnings growth is expected to accelerate in 2026.
Cigna Group, a manager of health care plans, benefited from the market’s perception that it is a more stable investment option than other health insurance companies in the current environment, given its minimal exposure to federal government spending and relatively low exposure to insurance risk. This stability has made it an attractive choice for investors amid economic uncertainty, contributing positively to its performance during the quarter.
In March, we purchased additional shares of Cigna (CI) in accounts that were underweighted in this position. This decision reflects our confidence in Cigna's business model and growth potential within the health care sector. The company's strong fundamentals and market position suggest it is well-equipped to navigate the evolving landscape of health care services, making it a valuable addition to our portfolio.
Press Release
Articles on The Cigna Group
Headlines
See More- 1
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
